Blonanserin

Quick links to important sections

Blonanserin

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blonanserin

Quick Facts

Property Description
Active ingredient Blonanserin (INN)
Form Tablet, Oral Powder
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic, SGA)
General purpose Mental stabilization and improved thought organization
Origin Synthetic compound

Blonanserin: Classification and Active Composition

Blonanserin is a synthetic, single-ingredient Second-Generation Antipsychotic (SGA) medicine used to stabilize mental health conditions associated with neurotransmitter imbalances in the brain. It is classified as an antipsychotic agent.

The active component is the compound Blonanserin (INN), a chemically synthesized molecule with the unique formula C23H30FN3. This synthetic compound is manufactured into its solid, oral preparation form, typically a tablet or oral powder, combined with necessary pharmaceutical excipients. The drug's defining characteristic is its role as a potent Dopamine-Serotonin Antagonist (DSA), which differentiates it from older antipsychotic classes.

Action and General Purpose of This Atypical Antipsychotic

The medicine primarily functions as a DSA, working to modulate key signaling pathways in the central nervous system to restore neurochemical balance. Blonanserin possesses a high affinity for both the D2 dopamine receptor and the 5-HT2A serotonin receptor.

The compound is recognized for its potential to help stabilize emotional and cognitive processes. The general purpose of this action is to achieve mental stabilization by reducing excessive signal transmission. For the patient, the intended benefit is the normalization of thinking processes, the reduction of disorganized symptoms, and the facilitation of a clearer, more rational perception of reality. Its balanced receptor profile is a key differentiating factor within the SGA class.

What side effects are possible with Blonanserin?

Possible Side Effects and Safety Information

The safety profile of Blonanserin, based on official regulatory documentation, is characterized by specific system-organ class effects, documented serious reactions, and defined safety constraints.

Adverse Reaction Scope

Category Description
Most Commonly Reported Parkinson's syndrome, Akathisia (restlessness), Insomnia, Dyskinesia (involuntary movements of face/mouth), and Drowsiness (Somnolence) are frequently documented.
System-Organ Classes Adverse events primarily involve the Nervous System (movement disorders), Metabolism and Nutrition (Hyperglycemia, weight gain), and the Endocrine system (Hyperprolactinemia).
Serious Adverse Reactions Officially listed severe reactions include Malignant Syndrome, Rhabdomyolysis, Paralytic Ileus, Tardive Dyskinesia, and acute complications related to Hyperglycemia (Diabetic Ketoacidosis, Diabetic Coma).

Safety Constraints and Considerations

Regulatory documents specify explicit limitations on use, including contraindication for patients in a coma or those with a history of serious conditions such as Malignant Syndrome, Rhabdomyolysis, or severe cardiovascular, liver, or kidney disease. The medicine is also noted to cause sleepiness or decrease of attention/concentration.

Regarding patient populations, adolescent patients have been documented to have a significantly higher incidence of Extrapyramidal Symptoms (EPS) and Akathisia during the initial treatment weeks, a pattern also observed for most adverse events occurring within the first 30 days of treatment initiation. The effects may also be intensified by the concurrent consumption of alcohol or grapefruit juice.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents regarding Blonanserin overdose focus primarily on mandated emergency actions and critical management constraints. If an excessive dose is accidentally ingested, it is officially required to consult with a doctor or pharmacist immediately.

The prescribing information does not formally detail a specific set of clinical signs or symptoms that exclusively define a Blonanserin overdose in its public sections. However, the management procedures are structured to address potentially severe physiological outcomes. Due to the drug's properties as an alpha-adrenergic blocking agent, a critical warning is issued regarding the risk of severe hypotension (a serious drop in blood pressure).

Management of a Blonanserin overdose involves providing symptomatic and supportive treatment. The official documentation states that no specific antidote is known for this medication. Furthermore, a specific and crucial constraint exists for medical professionals: the use of Adrenaline (Epinephrine) to manage low blood pressure in an overdose scenario is contraindicated. This is because Adrenaline can paradoxically worsen the hypotension, a reaction known as adrenaline reversal. Therefore, the regulatory profile directs care toward general supportive measures while strictly prohibiting the use of this specific vasopressor.

Therapeutic Uses of Blonanserin

What Blonanserin Treats: Main Uses and Benefits

Blonanserin is an atypical antipsychotic medication used for managing symptoms related to schizophrenia. It is approved in countries like Japan and South Korea for this therapeutic area of use. Specifically, the official indication for this drug is the treatment of schizophrenia.


This medication supports patients by applied in addressing symptom clusters that may become intense or disruptive. It helps manage both symptoms related to heightened physiological activity (often called positive symptoms) and symptoms that interfere with daily functioning (often called negative symptoms).

Blonanserin is commonly used across conditions presenting with acute episodes and in the condition involving episodic or fluctuating manifestations. It contributes to easing the overall symptom load during periods of heightened discomfort.

“This medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

It helps improve day-to-day comfort during symptomatic periods and offers symptomatic relief that helps patients cope more steadily.

Quick Fact: Applied in addressing symptoms that interfere with daily functioning

Regulatory References

  1. PMDA Report on Deliberation Results

Eligibility and Restrictions for Use

Who can and cannot use Blonanserin?

Blonanserin’s use is strictly defined by regulatory eligibility criteria regarding age, concurrent medications, and pre-existing medical conditions. The criteria outline which populations are approved, restricted, or prohibited from using the medicine.


Approved and Non-Eligible Populations

The medicine is officially approved for use in adult patients and in adolescents aged 12 to 18 years in jurisdictions where its use is established. Use is not established for children under 12 years of age.

Blonanserin is contraindicated (must not be used) in patients with known hypersensitivity to the drug. It is also prohibited for patients receiving specific strong CYP3A4 inhibitors (such as certain antifungal or HIV protease inhibitor medications) or Adrenaline (epinephrine), except during life-saving anaphylaxis treatment.


Restrictions and Special Considerations

Regulatory documentation specifies that use is not recommended during pregnancy or while breastfeeding. Special caution is required for elderly patients (ge 65 years). Use is restricted in patients with a history of or current serious conditions, including malignant syndrome, convulsive disease, or hepatic disorder. Administration also requires careful assessment in patients who are debilitated by dehydration or malnutrition.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Blonanserin has officially documented interaction patterns that primarily involve the body’s metabolic and signaling systems. The most critical restriction is the formal contraindication of co-administration with two substance classes. First, Blonanserin must not be used with Strong CYP3A4 Inhibitors, such as certain azole antifungal agents and HIV protease inhibitors, as these combinations lead to a severe increase in Blonanserin plasma concentration.

Second, Adrenaline (Epinephrine) is also contraindicated due to the risk of serious reductions in blood pressure.

Pharmacokinetic and Pharmacodynamic Cautions

Other medicines require caution due to pharmacokinetic (PK) interactions. Since Blonanserin is primarily metabolized by the CYP3A4 enzyme, co-administration with other CYP3A4 inhibitors (e.g., Erythromycin, Diltiazem) may increase drug exposure, while CYP3A4 inducers (e.g., Carbamazepine, Rifampicin) may decrease exposure.

Pharmacodynamic (PD) interactions are also noted. Caution is advised when combining Blonanserin with CNS Depressant drugs or Alcohol because this may enhance their effects. Conversely, the efficacy of Blonanserin may be reduced if taken with Dopamine Agonists, such as Levodopa.

Administration Constraints

A specific administration-timing constraint is required for adequate bioavailability: the medicine must be taken after meals, as taking it on an empty stomach may result in the expected efficacy not being obtained. Co-consumption of Grapefruit Juice is also strictly prohibited.

Mechanism of Action

Blonanserin's mechanism of action is defined by a highly selective profile of receptor antagonism within the central nervous system, focusing on key pathways and altering neurotransmitter activity.

Modulating Signal Transmission via D2 Antagonism

This action involves antagonism of the Dopamine D2 receptor, particularly within the mesolimbic pathway. The mechanistic cascade achieves high receptor occupancy, resulting in the attenuation of excessive dopaminergic signaling within neural circuits.

Serotonin-Dopamine Pathway Balancing

This mechanism involves the dual blockade of the D2 and Serotonin 5-HT2 A receptors, with a defining six-fold greater affinity for the D2 target. The 5-HT2 A antagonism acts as a crucial modulator, promoting DA release in the nigrostriatal and mesocortical pathways. This dual-pathway action influences motor pathway activity and alters neurotransmission in the prefrontal cortex.

Intracellular Specificity and D3 Modulation

Secondary action occurs at the D3 receptor, where interaction triggers an intracellular signaling cascade that potentiates Protein Kinase A ( PKA) activity, leading to modulation of Cl^- currents within the GABAergic system. This focused mechanism, alongside low affinity for non-target receptors ( H1, alpha1, M1), contributes to the drug's physiological influence being concentrated on the primary DA and 5-HT systems.

Dosage and Administration Information

How to Use Blonanserin

Blonanserin is available for oral administration and is provided in standardized tablet (2 mg, 4 mg, 8 mg) and oral powder formulations. The medicine is used according to specific administration principles.

Official Dosing and Administration Schedule

The general protocol for use involves dividing the total daily dose into two administrations to maintain consistent systemic levels. The medicine must be taken after meals because administration on an empty stomach may lead to reduced systemic exposure.

Adult Dosage: Treatment begins with a starting dose of 4 mg taken twice daily, totaling 8 mg per day. The dose is increased gradually (titrated) as specified in the treatment plan. The typical adult maintenance range is 8 to 16 mg daily, taken in divided doses, with the maximum recommended daily amount not exceeding 24 mg.

Pediatric Dosage: The pediatric starting dose is 2 mg twice daily (4 mg/day total). The dose is adjusted according to the patient's condition, with the maximum allowed daily dose limited to 16 mg.

Handling Missed Timing

If an administration is missed, the dose is taken after a meal or a light snack as soon as it is remembered. However, if the time for the next scheduled dose is approaching, the missed dose is skipped. Two doses must not be combined or taken together at one time to compensate for a missed administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blonanserin

Evidence for Use in Schizophrenia

The evidence base that was submitted for review included multiple randomized controlled trials (RCTs). Research was evaluated in conditions characterized by fluctuating or episodic manifestations, such as schizophrenia. Studies examined the medicine in trials against both inactive control (placebo) and several other established atypical antipsychotic agents. These short-term RCTs were primarily used in research exploring how symptoms change over time.

Research examined change in overall symptom severity when using the medicine, measured by specialized scales like the Positive and Negative Syndrome Scale (PANSS). Studies reported measurements of change in both positive symptom clusters (like hallucinations) and negative symptom clusters (like social withdrawal). Studies explored change in symptoms when this medicine was evaluated alongside other active comparator treatments.

Study Types and Outcomes Examined

The evidence landscape includes multiple systematic reviews and meta-analyses, which pool data from the initial double-blind RCTs to provide a broader context. Research has examined a variety of outcomes in addition to changes in core symptoms. Research examined outcomes monitored by assessments like the Personal and Social Performance (PSP) scale. The data show patterns related to cognitive measures. The primary goal of these studies was to monitor how patients evolved over defined time intervals and to provide insight into short-term changes in functioning and thinking processes.

Long-Term Follow-up and Treatment Maintenance

Short-term trials provided the primary evidence base for observed initial symptom changes. To address the need for extended observation, studies were conducted over intermediate periods (up to 26 weeks) and some retrospective and open-label studies monitored patient responses for up to 3 years. These extended studies were used in observational settings, and data show patterns related to treatment continuation and discontinuation rates over the observed periods. However, evidence is limited for long-term outcomes from randomized, controlled settings.

Key Studies & References

  1. Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials (2024)
  2. Improvement of social functioning in patients with first-episode schizophrenia using blonanserin treatment: a prospective, multi-centre, single-arm clinical trial

Frequently Asked Questions (FAQ)

Common questions about Blonanserin (FAQ)

Q: What kind of results can a person generally expect when starting Blonanserin?

Official information states that this medicine is designed to help stabilize brain chemistry, which may improve symptoms like strong anxiety, tense feelings, and lowered motivation. Although the drug starts to act quickly, clinical changes or symptom improvement is typically measured over a period of several weeks.


Q: Is Blonanserin meant to be a short-term or a long-term treatment?

Regulatory documents indicate Blonanserin is used both for the initial control of acute symptoms and for the long-term stabilization of chronic conditions. Official documents describe that cessation must occur only under the direction of a healthcare provider.


Q: Are the sleepiness and fatigue side effects from Blonanserin temporary?

Sleepiness and restlessness are common adverse effects reported in official safety summaries. Studies indicate that many common side effects are mild and may gradually lessen or resolve over time as the body adjusts to the medication.


Q: How long do common side effects usually last after starting this medicine?

Official patient information notes that most common side effects are generally mild and may gradually resolve. However, the exact duration of any specific side effect is not defined in the prescribing information. For any persistent symptoms, consultation with a healthcare professional is described as necessary.


Q: What are the signs of a serious problem related to Blonanserin that need urgent attention?

Rare but serious symptoms are described as conditions where immediate medical attention is necessary. These include high fever combined with muscle stiffness (Malignant Syndrome) or signs of acute high blood sugar, such as severe thirst and frequent urination (complications of Hyperglycemia).


Q: Are there any known long-term health risks associated with taking Blonanserin for years?

Long-term use requires monitoring for potential serious reactions, including involuntary movements (Tardive Dyskinesia) and metabolic changes. Clinical summaries indicate the safety profile is evaluated when patients are closely supervised.


Q: Does Blonanserin affect laboratory blood test results, such as liver function tests?

Regulatory documents require caution and monitoring of blood tests for patients with pre-existing liver or kidney impairment. While one clinical review noted no major changes in lab test results in general, regulatory documents note that metabolic changes are an associated risk.


Q: Is there a specific time of day that is considered best for taking Blonanserin?

Official administration rules state that the total daily dose must be divided into two separate administrations. Regulatory instructions describe that the medicine is required to be taken after meals for adequate absorption, regardless of the time of day chosen.


Q: Is Blonanserin considered a first-line or a second-line treatment option?

Official clinical summaries indicate that in some jurisdictions, the medicine has been studied and used for adult patients who have not fully responded to a first or initial course of treatment. The decision on its use is determined by a specialist based on the patient’s clinical history.


Q: How quickly should the effects of Blonanserin start to be noticed?

Pharmacokinetic data shows the medicine reaches its highest concentration in the bloodstream rapidly, typically within about 1.5 hours of administration. However, the time required for a patient to experience clinical changes or symptom improvement is typically measured over weeks of consistent use.


Q: Does Blonanserin cause dizziness when standing up suddenly?

General dizziness is listed as a possible adverse reaction in the safety documents. While some clinical reviews report a low risk of low blood pressure upon standing, regulatory documents advise that special assessment is required for patients with pre-existing low blood pressure.


Q: Does Blonanserin interact with common over-the-counter pain relievers like ibuprofen or aspirin?

Official patient instructions describe that caution is required regarding the use of all over-the-counter medicines, including pain relievers, and supplements. The official guidance states that combinations could potentially enhance or diminish the intended medicinal effects.


Q: Can Blonanserin be taken with common supplements like multivitamins or herbal teas?

Official regulatory information describes that caution is required with the co-administration of all dietary supplements and other medicines. These combinations carry a risk of enhancing or reducing the effects of Blonanserin.


Q: Why is Blonanserin available in some countries but not approved everywhere?

The availability of this medicine is currently restricted to certain markets, such as Japan and Korea, where it has received official regulatory approval. The non-availability in other regions is generally due to separate regulatory review processes and commercial decisions in those specific territories.


Q: Is Blonanserin habit-forming or addictive?

Official patient information and clinical summaries generally report that this medicine is not considered addictive or habit-forming. There have been no reports of dependence associated with its use.


Q: Is it described as safe to stop taking Blonanserin suddenly?

Official regulatory instructions clearly stipulate that cessation must only occur under the direction and supervision of a healthcare provider. Stopping the medicine suddenly is not recommended in the official product information.


Q: Can Blonanserin make anxiety or nervousness worse for some people?

Clinical data summarized in regulatory documents indicate that anxiety and irritability are listed among the adverse reactions reported by some patients. For any new or worsening feelings of nervousness, consultation with a healthcare provider is described as necessary.

How should Blonanserin be stored and disposed of?

How to Store and Dispose of Blonanserin

The official regulatory labeling provides specific requirements for storing and discarding Blonanserin tablets.

Storage Requirements

Blonanserin must be stored in a dry, cool, and well-ventilated place at standard room temperature (1 C to 30 C). It is mandatory to keep the medicine away from direct sunlight, heat, and moisture to preserve its stability. The product should be stored in a tightly closed container.

Child Safety

It is required to keep Blonanserin out of the reach of children.

Disposal Instructions

Official instructions mandate that patients must discard the remainder of any unused medicine and not store it. Unused Blonanserin must not be given to anyone else. Patients are instructed to seek advice from a pharmacy or medical institution for guidance on the proper method for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Blonanserin found in:

A-Z Index: